Cargando…
Cardioprotective Agents for the Primary Prevention of Trastuzumab-Associated Cardiotoxicity: A Systematic Review and Meta-Analysis
There are significant considerations about the prevention of cardiotoxicity caused by trastuzumab therapy in patients with breast cancer, leading to discontinuation. Recently, randomized controlled trials (RCTs) have evaluated the effects of early commitment of beta-blockers (BBs), angiotensin recep...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10383255/ https://www.ncbi.nlm.nih.gov/pubmed/37513895 http://dx.doi.org/10.3390/ph16070983 |
_version_ | 1785080863737774080 |
---|---|
author | Goulas, Kyriakos Farmakis, Dimitrios Constantinidou, Anastasia Kadoglou, Nikolaos P. E. |
author_facet | Goulas, Kyriakos Farmakis, Dimitrios Constantinidou, Anastasia Kadoglou, Nikolaos P. E. |
author_sort | Goulas, Kyriakos |
collection | PubMed |
description | There are significant considerations about the prevention of cardiotoxicity caused by trastuzumab therapy in patients with breast cancer, leading to discontinuation. Recently, randomized controlled trials (RCTs) have evaluated the effects of early commitment of beta-blockers (BBs), angiotensin receptor blockers (ARBs) and angiotensin converting enzyme inhibitors (ACEIs) during trastuzumab chemotherapy in order to prevent the related cardiotoxicity. The present systematic review and meta-analysis of six RCTs included patients who have predominantly non-metastatic, HER2-positive, breast cancer and received trastuzumab as primary or adjuvant therapy. Those patients did not have any obvious cardiac dysfunction or any previous therapy with cardioprotective agent. We evaluated the efficacy of the aforementioned medications for primary prevention of cardiotoxicity, using random effects models. Any preventive treatment did not reduce cardiotoxicity occurrence compared to controls (Odds ratios (OR) = 0.92, 95% CI 0.54–1.56, p = 0.75). Results were similar for ACEIs/ARBs and beta-blockers. Treatment with ACEIs/ARBs led to a slight, but significant, increase in LVEF in patients compared to the placebo group. Only two studies reported less likelihood of discontinuation of trastuzumab treatment. More adequately powered RCTs are needed to determine the efficacy of routine prophylactic therapy. |
format | Online Article Text |
id | pubmed-10383255 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103832552023-07-30 Cardioprotective Agents for the Primary Prevention of Trastuzumab-Associated Cardiotoxicity: A Systematic Review and Meta-Analysis Goulas, Kyriakos Farmakis, Dimitrios Constantinidou, Anastasia Kadoglou, Nikolaos P. E. Pharmaceuticals (Basel) Systematic Review There are significant considerations about the prevention of cardiotoxicity caused by trastuzumab therapy in patients with breast cancer, leading to discontinuation. Recently, randomized controlled trials (RCTs) have evaluated the effects of early commitment of beta-blockers (BBs), angiotensin receptor blockers (ARBs) and angiotensin converting enzyme inhibitors (ACEIs) during trastuzumab chemotherapy in order to prevent the related cardiotoxicity. The present systematic review and meta-analysis of six RCTs included patients who have predominantly non-metastatic, HER2-positive, breast cancer and received trastuzumab as primary or adjuvant therapy. Those patients did not have any obvious cardiac dysfunction or any previous therapy with cardioprotective agent. We evaluated the efficacy of the aforementioned medications for primary prevention of cardiotoxicity, using random effects models. Any preventive treatment did not reduce cardiotoxicity occurrence compared to controls (Odds ratios (OR) = 0.92, 95% CI 0.54–1.56, p = 0.75). Results were similar for ACEIs/ARBs and beta-blockers. Treatment with ACEIs/ARBs led to a slight, but significant, increase in LVEF in patients compared to the placebo group. Only two studies reported less likelihood of discontinuation of trastuzumab treatment. More adequately powered RCTs are needed to determine the efficacy of routine prophylactic therapy. MDPI 2023-07-09 /pmc/articles/PMC10383255/ /pubmed/37513895 http://dx.doi.org/10.3390/ph16070983 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Systematic Review Goulas, Kyriakos Farmakis, Dimitrios Constantinidou, Anastasia Kadoglou, Nikolaos P. E. Cardioprotective Agents for the Primary Prevention of Trastuzumab-Associated Cardiotoxicity: A Systematic Review and Meta-Analysis |
title | Cardioprotective Agents for the Primary Prevention of Trastuzumab-Associated Cardiotoxicity: A Systematic Review and Meta-Analysis |
title_full | Cardioprotective Agents for the Primary Prevention of Trastuzumab-Associated Cardiotoxicity: A Systematic Review and Meta-Analysis |
title_fullStr | Cardioprotective Agents for the Primary Prevention of Trastuzumab-Associated Cardiotoxicity: A Systematic Review and Meta-Analysis |
title_full_unstemmed | Cardioprotective Agents for the Primary Prevention of Trastuzumab-Associated Cardiotoxicity: A Systematic Review and Meta-Analysis |
title_short | Cardioprotective Agents for the Primary Prevention of Trastuzumab-Associated Cardiotoxicity: A Systematic Review and Meta-Analysis |
title_sort | cardioprotective agents for the primary prevention of trastuzumab-associated cardiotoxicity: a systematic review and meta-analysis |
topic | Systematic Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10383255/ https://www.ncbi.nlm.nih.gov/pubmed/37513895 http://dx.doi.org/10.3390/ph16070983 |
work_keys_str_mv | AT goulaskyriakos cardioprotectiveagentsfortheprimarypreventionoftrastuzumabassociatedcardiotoxicityasystematicreviewandmetaanalysis AT farmakisdimitrios cardioprotectiveagentsfortheprimarypreventionoftrastuzumabassociatedcardiotoxicityasystematicreviewandmetaanalysis AT constantinidouanastasia cardioprotectiveagentsfortheprimarypreventionoftrastuzumabassociatedcardiotoxicityasystematicreviewandmetaanalysis AT kadoglounikolaospe cardioprotectiveagentsfortheprimarypreventionoftrastuzumabassociatedcardiotoxicityasystematicreviewandmetaanalysis |